1
Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2
Department of Internal Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
3
School of Medicine, Iran University of Medical Sciences, Tehran, Iran
4
Department of Infectious Diseases, School of Medicine, Iran university of Medical Sciences, Tehran, Iran.
Abstract
Background: Pulmonary tuberculosis (TB) and invasive aspergillosis are distinct infectious diseases that rarely coexist in the same patient. The concurrent occurrence of these infections presents diagnostic and therapeutic challenges, resulting in complex clinical presentations and potentially adverse outcomes. We present a case report highlighting the diagnostic process, management strategies, and pertinent literature regarding the simultaneous occurrence of pulmonary TB and aspergillosis in a patient following COVID-19 infection. Case Presentation: A 55-year-old male with a history of occupational exposure as a farmer and welder presented with a complex medical condition. He had a previous COVID-19 infection and was hospitalized for three weeks, receiving appropriate treatment. Subsequently, he developed dyspnea and bilateral pleural effusion and underwent treatment with broad-spectrum antibiotics. Further investigations revealed consolidation in the left upper lobe, and biopsy confirmed the presence of Aspergillus species. The patient received voriconazole treatment for several months, but minimal improvement was observed. Recurrent hemoptysis prompted bronchoscopy, which showed positive results for acid-fast bacilli smear and TB PCR testing, indicating concomitant pulmonary TB. Anti-tuberculosis treatment was initiated alongside ongoing management for aspergillosis. Conclusion: This case report illustrates the diagnostic and therapeutic complexities associated with the simultaneous occurrence of pulmonary TB and aspergillosis in a patient following COVID-19 infection. Clinicians should maintain a high index of suspicion for dual infections in similar clinical scenarios. Prompt recognition, accurate diagnosis, and individualized treatment strategies are crucial for optimal patient management. Further research is warranted to enhance our understanding of this unique clinical entity and improve patient outcomes.
Talebi-Taher,M. , Javad-Moosavi,S. A. , Ahmadalipour,S. , Bahrami,M. , Sarkheil,M. and Javad-Moosavi,A. (2025). Invasive Pulmonary Aspergillosis and Tuberculosis after COVID-19. TANAFFOS (Respiration), 24(1), 102-105.
MLA
Talebi-Taher,M. , , Javad-Moosavi,S. A. , , Ahmadalipour,S. , , Bahrami,M. , , Sarkheil,M. , and Javad-Moosavi,A. . "Invasive Pulmonary Aspergillosis and Tuberculosis after COVID-19", TANAFFOS (Respiration), 24, 1, 2025, 102-105.
HARVARD
Talebi-Taher M., Javad-Moosavi S. A., Ahmadalipour S., Bahrami M., Sarkheil M., Javad-Moosavi A. (2025). 'Invasive Pulmonary Aspergillosis and Tuberculosis after COVID-19', TANAFFOS (Respiration), 24(1), pp. 102-105.
CHICAGO
M. Talebi-Taher, S. A. Javad-Moosavi, S. Ahmadalipour, M. Bahrami, M. Sarkheil and A. Javad-Moosavi, "Invasive Pulmonary Aspergillosis and Tuberculosis after COVID-19," TANAFFOS (Respiration), 24 1 (2025): 102-105,
VANCOUVER
Talebi-Taher M., Javad-Moosavi S. A., Ahmadalipour S., Bahrami M., Sarkheil M., Javad-Moosavi A. Invasive Pulmonary Aspergillosis and Tuberculosis after COVID-19. TANAFFOS (Respiration), 2025; 24(1): 102-105.
